Enhance your knowledge of CCA by listening to experts give their
perspectives on key topics in the educational videos below*
World CCA Day (12 February 2022), organised by the Global CCA Alliance, is an international effort to raise
awareness of CCA. The purpose of Rare Disease Day (28 February 2022) is to raise awareness and generate
change for the 300 million people worldwide living with a rare disease.1 To support these initiatives, we asked
a patient with CCA and a multidisciplinary panel of CCA experts to express how they #SeeCCA today.
This online webinar took place on 26 February 2021 and was hosted by our esteemed faculty who critically discussed the complexity of diagnosing CCA and the clinical and genetic heterogeneity associated with the disease
Company/Organisation | Relationship(s) |
---|---|
Incyte | Speaker |
Company/Organisation | Relationship(s) |
---|---|
Patient, no conflict of interest. |
Company/Organisation | Relationship(s) |
---|---|
Albireo Pharma, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eisai, GenFit, Nutricia Ipsen, QED, Roche, Servier and TransThera Biosciences | Receipt of honoraria or consultation fees |
AAA, AstraZeneca, Eisai, Incyte, Ipsen, Merck, Pfizer, QED, Roche and Servier | Participation in company-sponsored speaker bureau |
AAA, Bayer, Delcath, Ipsen, Mylan, Novartis, Pfizer and Sirtex | Travel, education funding |
Ipsen and Roche | Research funding |
Company/Organisation | Relationship(s) |
---|---|
Bristol Myers Squibb, Bayer, Eisai, Gilead, Incyte, Intercept, Ipsen, MDS, Roche, Sanofi, Sigma-Tau | Consulting honoraria and advisory boards |
Company/Organisation | Relationship(s) |
---|---|
Imaging Equipment Ltd, Ipsen, Novartis, NuCana | Speakers bureau |
Celgene, NuCana | Travel grant |
Agios, AstraZeneca, Debiopharm, Delcath Systems, GenoScience Pharma, Imaging Equipment Ltd, Incyte, Ipsen, Keocyt, Merck, Mundipharma EDO, Novartis, NuCana, PCI Biotech, Pieris Pharmaceuticals, Pfizer, QED, Servier, Wren Laboratories | Grant support |
Company/Organisation | Relationship(s) |
---|---|
Amgen, AstraZeneca, Baxter, Bayer, BMS, Dach, Humedics, Incyte, Merck-Serono, MSD, Olympus, Roche, Servier | Research funding/speaker bureau/advisory role |
Company/Organisation | Relationship(s) |
---|---|
Adaptimmune, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Eisai, Exelixis, Ipsen, Lilly, Merck, Novartis, Roche, Sirtex Medical, Terumo | Consulting, advisory role or honoraria |
Bristol Myers Squibb, Sirtex Medical | Grants |
Company/Organisation | Relationship(s) |
---|---|
Ability Pharmaceuticals SL, Aptitude Health, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, Ellipses, Genzyme, Got It Consulting SL, Hirslanden/GITZ, Imedex, Incyte, Ipsen Bioscience Inc, Janssen, Lilly, Marketing Farmacéutico & Investigación Clínica S.L, MDS, Medscape, Novocure, Paraxel, Polaris, PPD Development, QED Therapeutics, Roche Farma, Sanofi-Aventis, Scilink Comunicación Científica SC, Servier, Surface Oncology, Swedish Orphan Biovitrum AB, Zymeworks | Advisory role Speaker’s fee Direct research fund |
AbbVie Farmaceútica, Ability Pharmaceuticals, Agios Pharmaceuticals, Amc Medical Research, Amgen, Armo Biosciences, Aslan Pharmaceuticals, Astrazeneca, Basilea Pharmaceutica International, Bayer, Beigene, Biokeralty Research Institute, Biolinerx, Blueprint Medicines, Boston Biomedical, Bristol-Myers Squibb (BMS), Cantargia, Celgene, Eisai, Erytech Pharma, F. Hoffmann-la Roche, Fibrogen, Halozyme, Incyte, Ipsen Bioscience, Ipsen Pharma, Lilly, Loxo Oncology, Medimmune, Merck Sharp & Dohme, Nelum, Novartis, Novocure, Oncomed Pharmaceuticals, QED Therapeutics, VCN Biosciences, Zymeworks | Clinical trial support |
Company/Organisation | Relationship(s) |
---|---|
Bayer, BMS, Guardant Health, Incyte, Merck, Novartis, Roche | Advisory board |
Company/Organisation | Relationship(s) |
---|---|
Dietician, no disclosures reported. |
Company/Organisation | Relationship(s) |
---|---|
Ability Pharmaceuticals SL, Aptitude Health, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, Ellipses, Genzyme, Got It Consulting SL, Hirslanden/GITZ, Imedex, Incyte, Ipsen Bioscience Inc, Janssen, Lilly, Marketing Farmacéutico & Investigación Clínica S.L, MDS, Medscape, Novocure, Paraxel, Polaris, PPD Development, QED Therapeutics, Roche Farma, Sanofi-Aventis, Scilink Comunicación Científica SC, Servier, Surface Oncology, Swedish Orphan Biovitrum AB, Zymeworks | Advisory role Speaker’s fee Direct research fund |
AbbVie Farmaceútica, Ability Pharmaceuticals, Agios Pharmaceuticals, Amc Medical Research, Amgen, Armo Biosciences, Aslan Pharmaceuticals, Astrazeneca, Basilea Pharmaceutica International, Bayer, Beigene, Biokeralty Research Institute, Biolinerx, Blueprint Medicines, Boston Biomedical, Bristol-Myers Squibb (BMS), Cantargia, Celgene, Eisai, Erytech Pharma, F. Hoffmann-la Roche, Fibrogen, Halozyme, Incyte, Ipsen Bioscience, Ipsen Pharma, Lilly, Loxo Oncology, Medimmune, Merck Sharp & Dohme, Nelum, Novartis, Novocure, Oncomed Pharmaceuticals, QED Therapeutics, VCN Biosciences, Zymeworks | Clinical trial support |
Company/Organisation | Relationship(s) |
---|---|
Bristol Myers Squibb, Bayer, Eisai, Gilead, Incyte, Intercept, Ipsen, MDS, Roche, Sanofi, Sigma-Tau | Consulting honoraria and advisory boards |
Company/Organisation | Relationship(s) |
---|---|
Albireo Pharma, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eisai, GenFit, Nutricia Ipsen, QED, Roche, Servier and TransThera Biosciences | Receipt of honoraria or consultation fees |
AAA, AstraZeneca, Eisai, Incyte, Ipsen, Merck, Pfizer, QED, Roche and Servier | Participation in company-sponsored speaker bureau |
AAA, Bayer, Delcath, Ipsen, Mylan, Novartis, Pfizer and Sirtex | Travel, education funding |
Ipsen and Roche | Research funding |
Company/Organisation | Relationship(s) |
---|---|
Incyte Biosciences International Sàrl | Former employee (01 May 2020 – 31 May 2022) |
You are now leaving Cholangiocarcinoma-eu.com. This link will take you to a site that is not owned or maintained by Incyte, and Incyte is not responsible for the information contained on third-party sites.
Please select from the following: